Key facts
- Bexion Pharmaceuticals’s last known valuation is $82.1M (Dec 2017).
- It has raised $56.0M.
- Notable investors include Keyhorse Capital, CancerFree KIDS, Michael J. Fox Foundation, National Cancer Institute, Seedfunders — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Bexion Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Bexion Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bexion Pharmaceuticals
Operator of a biotechnology company intended to develop biologics targeting sphingolipid metabolism. The company helps to treat solid tumors and chemotherapy-induced peripheral neuropathy, enabling health professionals to program cell death, reduce proliferation, and immune system.
- Sector
- Healthcare
- HQ
- Covington, KY, United States
- Founded
- 2006
- Employees
- 22
- Website
- bexionpharma.com/
- Ownership
- Privately Held (backing)
Bexion Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bexion Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bexion Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.